TSX:BHC (Bausch Health Companies)

About BHC

Bausch Health Cos., Inc. engages in the development, manufacture and market of a range of branded, generic and branded generic pharmaceuticals, medical devices and over-the-counter products. It operates through the following segments: Salix, International, Solta Medical, Diversified Products, and Bausch + Lomb. The Salix segment consists of sales in the U.S. of GI products. Sales of the Xifaxan product line. The International segment comprises of sales, with the exception of sales of Bausch + Lomb products and Solta aesthetic medical devices, outside the U.S and Puerto Rico of branded pharmaceutical products, branded generic pharmaceutical and OTC products. The Solta Medical segment refer to global sales of Solta Medical aesthetic medical devices. The Diversified Products segment covers sales in the U.S. of pharmaceutical products in the areas of neurology and certain other therapeutic classes, generic products, ortho dermatologics, and dentistry products. The Bausch + Lomb segment are global sales of Bausch + Lomb vision care, surgical and ophthalmic pharmaceuticals products. The company was founded on March 29, 1994 and is headquartered in Laval, Canada.
  • Bausch Health Companies (TSX: BHC) Latest News

    The Motley Fool
    Investing

    Why Is Valeant Pharmaceuticals Intl Inc. up 30% Since June 1?

    Valeant Pharmaceuticals Intl Inc. (TSX:VRX)(NYSE:VRX) has multiple debt-repayment strategies, but with shares up so much already, wait for a pullback.

    Read more »

    The Motley Fool
    Investing

    Valeant Pharmaceuticals Intl Inc. With Papa Is a Great Buy

    Valeant Pharmaceuticals Intl Inc. (TSX:VRX)(NYSE:VRX) has been a tough stock to own up until a few months ago. Here's why…

    Read more »

    Investing

    This 1 Company May Still Be the Best Contrarian Play of the Year

    Here's why Valeant Pharmaceuticals Intl Inc. (TSX:VRX)(NYSE:VRX) may still be one of the best contrarian plays for 2017.

    Read more »

    The Motley Fool
    Investing

    Can Joe Papa Make Valeant Pharmaceuticals Intl Inc. a High Flyer Again?

    Valeant Pharmaceuticals Intl Inc. (TSX:VRX)(NYSE:VRX) is starting to look like a great contrarian play. Should you load up today?

    Read more »

    The Motley Fool
    Investing

    What’s the Next Stop for Valeant Pharmaceuticals Intl Inc.?

    With a little tailwind, investors still need to be cautious of Valeant Pharmaceuticals Intl Inc. (TSX:VRX)(NYSE:VRX).

    Read more »

    The Motley Fool
    Investing

    Will Donald Trump Give Valeant Pharmaceuticals Intl Inc. a Much-Needed Lifeline?

    Valeant Pharmaceuticals Intl Inc. (TSX:VRX)(NYSE:VRX) stock jumped 28% this week. What’s brewing?

    Read more »

    The Motley Fool
    Investing

    Is Valeant Pharmaceuticals Intl Inc. a Viable Investment Opportunity?

    Valeant Pharmaceuticals Intl Inc. (TSX:VRX)(NYSE:VRX) continues to chip away at a staggering amount of debt and transition to a more…

    Read more »

    The Motley Fool
    Investing

    Valeant Pharmaceuticals Intl Inc. vs. Jean Coutu Group PJC Inc.: Is the Drug Maker or Drug Retailer a Buy?

    Valeant Pharmaceuticals Intl Inc. (TSX:VRX)(NYSE:VRX) is a drug producer, while Jean Coutu Group PJC Inc. (TSX:PJC.A) is a drug retailer.…

    Read more »

    The Motley Fool
    Investing

    Valeant Pharmaceuticals Intl Inc.: When Is a Good Time to Invest?

    Valeant Pharmaceuticals Intl Inc. (TSX:VRX)(NYSE:VRX) continues to achieve its goal of paying down its debt, but there's a lot of…

    Read more »

    The Motley Fool
    Investing

    Valeant Pharmaceuticals Intl Inc. Takes Another Step Closer to Death

    After unloading another business, Valeant Pharmaceuticals Intl Inc. (TSX:VRX)(NYSE:VRX) is another step closer to being crippled by the interest expenses.

    Read more »

    The Motley Fool
    Investing

    Get ‘Em While They’re Hot: Shares of Valeant Pharmaceuticals Intl Inc. Climb

    Valeant Pharmaceuticals Intl Inc. (TSX:VRX)(NYSE:VRX) has continued to make headway towards its proposed $5 billion debt-repayment schedule set for February…

    Read more »

    The Motley Fool
    Investing

    Valeant Pharmaceuticals Intl Inc. May Raise Another US$2 Billion to Pay Back Debt: Time to Buy?

    Valeant Pharmaceuticals Intl Inc. (TSX:VRX)(NYSE:VRX) made another deal. Is Valeant well positioned to meet its goal of debt repayment? Is…

    Read more »